Clinical trials
Diabetes Mellitus trials in Spain with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
34 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2007 | 2 |
| 2009 | 2 |
| 2011 | 2 |
| 2012 | 2 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 34 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Spanish Society of Cardiology | 2 |
| Universidad Complutense de Madrid | 2 |
| Universidad de Granada | 2 |
| Andalusian School of Public Health | 1 |
| Biotronik AG | 1 |
| Castilla-La Mancha Health Service | 1 |
| Complejo Hospitalario Universitario de Albacete | 1 |
| Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina | 1 |
| Fundacion Investigacion Interhospitalaria Cardiovascular | 1 |
| Fundació Sant Joan de Déu | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus | 34 |
| Pulmonary Disease, Chronic Obstructive | 7 |
| Hypertension | 6 |
| Obesity | 6 |
| Coronary Artery Disease | 4 |
| Heart Failure | 4 |
| Cardiovascular Diseases | 3 |
| Diabetes Mellitus, Type 2 | 3 |
| Malnutrition | 3 |
| Asthma | 2 |
Trials
Showing 1 to 25 of 34. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.